CY1105803T1 - Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου - Google Patents

Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου

Info

Publication number
CY1105803T1
CY1105803T1 CY20061101699T CY061101699T CY1105803T1 CY 1105803 T1 CY1105803 T1 CY 1105803T1 CY 20061101699 T CY20061101699 T CY 20061101699T CY 061101699 T CY061101699 T CY 061101699T CY 1105803 T1 CY1105803 T1 CY 1105803T1
Authority
CY
Cyprus
Prior art keywords
cancer
treatment
pepilamvanous
camptothekin
composition
Prior art date
Application number
CY20061101699T
Other languages
English (en)
Inventor
Marie-Christine Bissery
Original Assignee
Pfizer Enterpises Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Enterpises Sarl filed Critical Pfizer Enterpises Sarl
Publication of CY1105803T1 publication Critical patent/CY1105803T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Περιγράφονται θεραπευτικές φαρμακευτικές συνθέσεις που περιλαμβάνουν παράγωγο πυριμιδίνης σε συνδυασμό με καμπτοθεκίνη ή ένα παράγωγο καμπτοθεκίνης για τη θεραπεία καρκίνου. Σε μια πραγματοποίηση, το παράγωγο πυριμιδίνης είναι καπεσιταμπίνη και το παράγωγο καμπτοθεκίνης είναι CPT-11.
CY20061101699T 2000-02-28 2006-11-24 Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου CY1105803T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18537800P 2000-02-28 2000-02-28
US20893800P 2000-06-05 2000-06-05
PCT/EP2001/002723 WO2001062235A2 (en) 2000-02-28 2001-02-26 A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1105803T1 true CY1105803T1 (el) 2011-02-02

Family

ID=26881090

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101699T CY1105803T1 (el) 2000-02-28 2006-11-24 Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου

Country Status (28)

Country Link
US (3) US6503889B2 (el)
EP (1) EP1278518B1 (el)
JP (1) JP2003523980A (el)
KR (1) KR100717916B1 (el)
CN (1) CN1424912A (el)
AT (1) ATE344670T1 (el)
AU (1) AU785467B2 (el)
BR (1) BR0108728A (el)
CA (1) CA2401191C (el)
CY (1) CY1105803T1 (el)
CZ (1) CZ298259B6 (el)
DE (1) DE60124387T2 (el)
DK (1) DK1278518T3 (el)
EA (1) EA005619B1 (el)
EE (1) EE200200471A (el)
ES (1) ES2273841T3 (el)
HR (1) HRP20020658A2 (el)
HU (1) HUP0300848A3 (el)
IL (1) IL150953A0 (el)
MX (1) MXPA02008355A (el)
NO (1) NO324772B1 (el)
NZ (1) NZ520593A (el)
PL (1) PL363110A1 (el)
PT (1) PT1278518E (el)
SK (1) SK12242002A3 (el)
TW (1) TWI239841B (el)
WO (1) WO2001062235A2 (el)
YU (1) YU64602A (el)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20030092608A1 (en) * 2001-08-21 2003-05-15 Takayuki Kawaguchi Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
WO2004034787A1 (en) * 2002-10-17 2004-04-29 New York University Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil
ITMI20030317A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Terapia combinata comprendente un derivato dell'indolopirrolocarbazolo ed un altro agente antitumorale.
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
PT1689404E (pt) * 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
UA88008C2 (en) 2004-04-09 2009-09-10 Чугей Сейяку Кабусики Кайся Water-soluble prodrugs
JP2008501007A (ja) * 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク 異常な細胞増殖を治療するための方法
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
CA2569139A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer
US8569277B2 (en) * 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
ES2327195B1 (es) * 2005-04-12 2010-07-09 Elan Pharma International Limited Composiciones de liberacion modificada que comprenden un derivado de fluorocitidina para el tratamiento del cancer.
WO2006133092A1 (en) * 2005-06-07 2006-12-14 Yale University Methods of treating cancer and other conditions or disease states using lfmau and ldt
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
JP5858906B2 (ja) 2009-05-04 2016-02-10 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 多孔質シリコン薬物溶出粒子
HUE027831T2 (en) * 2010-03-12 2016-11-28 Genzyme Corp Combination therapy for breast cancer
WO2012061377A1 (en) 2010-11-01 2012-05-10 Psivida Us, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
JP2016512839A (ja) 2013-03-15 2016-05-09 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 治療物質の送達のための生体内分解性ケイ素系組成物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57116074A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Novel camptothecin derivative and its preparation
JPS57116015A (en) 1981-01-09 1982-07-19 Yakult Honsha Co Ltd Antitumor agent
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS595188A (ja) 1982-06-30 1984-01-12 Yakult Honsha Co Ltd １０−ヒドロキシカンプトテシンの製造法
JPS5951289A (ja) 1982-09-17 1984-03-24 Yakult Honsha Co Ltd 新規な９−置換−カンプトテシン誘導体
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
JP2524803B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体およびその製造法
JP2524804B2 (ja) 1988-03-29 1996-08-14 株式会社ヤクルト本社 新規なカンプトテシン誘導体及びその製造法
US5552154A (en) * 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
DE69209969T2 (de) 1991-10-29 1996-09-12 Glaxo Wellcome Inc Wasserlösliche Camptothecinderivate
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
CN1114608C (zh) 1995-06-21 2003-07-16 科学研究与运用咨询公司 喜树碱类似物、其制备方法和药物应用及其药物组合物
JP2002533360A (ja) * 1998-12-31 2002-10-08 スージェン・インコーポレーテッド 蛋白質キナーゼ活性を調節するためおよび癌の化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds

Also Published As

Publication number Publication date
WO2001062235A3 (en) 2002-11-14
JP2003523980A (ja) 2003-08-12
HUP0300848A2 (hu) 2003-08-28
NZ520593A (en) 2004-10-29
TWI239841B (en) 2005-09-21
US6664242B2 (en) 2003-12-16
EP1278518B1 (en) 2006-11-08
PL363110A1 (en) 2004-11-15
BR0108728A (pt) 2003-12-30
IL150953A0 (en) 2003-02-12
NO20024076L (no) 2002-08-27
DE60124387T2 (de) 2007-10-11
CA2401191A1 (en) 2001-08-30
EA200200922A1 (ru) 2003-04-24
HUP0300848A3 (en) 2005-03-29
EE200200471A (et) 2003-12-15
US20020091132A1 (en) 2002-07-11
US6503889B2 (en) 2003-01-07
ATE344670T1 (de) 2006-11-15
CN1424912A (zh) 2003-06-18
US20020068743A1 (en) 2002-06-06
CZ298259B6 (cs) 2007-08-08
KR100717916B1 (ko) 2007-05-11
HRP20020658A2 (en) 2004-12-31
PT1278518E (pt) 2007-01-31
NO324772B1 (no) 2007-12-10
ES2273841T3 (es) 2007-05-16
AU6011101A (en) 2001-09-03
NO20024076D0 (no) 2002-08-27
CA2401191C (en) 2006-05-02
DE60124387D1 (de) 2006-12-21
DK1278518T3 (da) 2007-01-15
KR20020082856A (ko) 2002-10-31
EA005619B1 (ru) 2005-04-28
MXPA02008355A (es) 2002-12-13
EP1278518A2 (en) 2003-01-29
WO2001062235A2 (en) 2001-08-30
SK12242002A3 (sk) 2003-02-04
AU785467B2 (en) 2007-07-26
CZ20022892A3 (cs) 2002-11-13
US20030096789A1 (en) 2003-05-22
YU64602A (sh) 2005-06-10

Similar Documents

Publication Publication Date Title
CY1105803T1 (el) Συνθεση πepιλαμβανουσα καμπτοθεκινη και ενα παραγωγο πυριμιδινης για τη θepαπεια καρκινου
CY1116103T1 (el) Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης
TR200200717T2 (tr) Terapötik kinazolin türevleri.
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
CY1108339T1 (el) Παραγωγα spiro(2h-1-benzopyran-2,4´-piperidine) ως αναστολεις της μεταφορας γλυκινης
CY1108408T1 (el) Παραγωγα διαζεπινοϊνδολιου ως αναστολεις κινασης
CY1114708T1 (el) Παραγωγα πυραζολο-κιναζολινης, διαδικασια για την παρασκευη τους και η χρηση τους ως αναστολεων κινασης
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
CY1117217T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
PT1017675E (pt) Derivados da camtotecina altamente lipofilos
NO20035699D0 (no) Farmasöytiske sammensetninger omfattende lav-opplöslighet og/eller syre-sensitive medikamenter og nöytraliserte sure polymerer
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
ATE236147T1 (de) Derivate von flavonen, xanthonen und kumarinen
CY1114422T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας
CY1106449T1 (el) Βελτιωμενη μεθοδος για εκριζωση του helicobacter pylori
CY1108890T1 (el) 7-ιμινο παραγωγα καμπτοθεκινης που εχουν αντιογκικη δραση
DE60229287D1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
DE60026046D1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
NO20031410D0 (no) Antitumorterapi innbefattende distamycinderivater
NO20054723L (no) Behandling av proliferative sykdommer med epofilonderivater og straling
HUP0302629A2 (hu) Camptotechin és sztilbénszármazékok kombinációját tartalmazó gyógyszerkészítmények rák kezelésére
UY26498A1 (es) Pirroles sustituidos
NO20055888L (no) Kombinasjonsterapi
CY1115806T1 (el) Παραγωγα του κυκλικου eστερα uk-2a χρησιμα στην προληψη ή την αντιμετωπιση μυκητολογικων ασθενειων
ECSP003846A (es) Pirroles sustituidos